Annual Cash & Cash Equivalents:
$919.37M+$238.41M(+35.01%)Summary
- As of today, ARWR annual cash & cash equivalents is $919.37 million, with the most recent change of +$238.41 million (+35.01%) on September 30, 2025.
- During the last 3 years, ARWR annual cash & cash equivalents has risen by +$542.97 million (+144.25%).
- ARWR annual cash & cash equivalents is now at all-time high.
Performance
ARWR Cash and Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly Cash & Cash Equivalents:
$919.37M+$18.99M(+2.11%)Summary
- As of today, ARWR quarterly cash & cash equivalents is $919.37 million, with the most recent change of +$18.99 million (+2.11%) on September 1, 2025.
- Over the past year, ARWR quarterly cash & cash equivalents has increased by +$238.41 million (+35.01%).
- ARWR quarterly cash & cash equivalents is now -16.22% below its all-time high of $1.10 billion, reached on March 31, 2025.
Performance
ARWR Quarterly Cash & Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ARWR Cash and Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1Y1 Year | +35.0% | +35.0% |
| 3Y3 Years | +144.3% | +144.3% |
| 5Y5 Years | +191.4% | +191.4% |
ARWR Cash and Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | |
|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +144.3% | -16.2% | +317.4% |
| 5Y | 5-Year | at high | +191.4% | -16.2% | +317.4% |
| All-Time | All-Time | at high | >+9999.0% | -16.2% | >+9999.0% |
ARWR Cash and Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2025 | $919.37M(+35.0%) | - |
| Sep 2025 | - | $919.37M(+2.1%) |
| Jun 2025 | - | $900.37M(-18.0%) |
| Mar 2025 | - | $1.10B(+98.5%) |
| Dec 2024 | - | $552.93M(-18.8%) |
| Sep 2024 | $680.96M(+68.7%) | $680.96M(+55.9%) |
| Jun 2024 | - | $436.67M(-16.5%) |
| Mar 2024 | - | $523.11M(+137.5%) |
| Dec 2023 | - | $220.28M(-45.4%) |
| Sep 2023 | $403.63M(+7.2%) | $403.63M(-10.6%) |
| Jun 2023 | - | $451.70M(-6.1%) |
| Mar 2023 | - | $481.00M(-4.2%) |
| Dec 2022 | - | $501.83M(+33.3%) |
| Sep 2022 | $376.40M(+2.3%) | $376.40M(-9.6%) |
| Jun 2022 | - | $416.50M(+3.6%) |
| Mar 2022 | - | $401.89M(+21.7%) |
| Dec 2021 | - | $330.13M(-10.2%) |
| Sep 2021 | $367.79M(+16.6%) | $367.79M(-28.8%) |
| Jun 2021 | - | $516.31M(-10.6%) |
| Mar 2021 | - | $577.32M(+89.1%) |
| Dec 2020 | - | $305.33M(-3.2%) |
| Sep 2020 | $315.49M(+22.0%) | $315.49M(+9.9%) |
| Jun 2020 | - | $287.03M(-6.7%) |
| Mar 2020 | - | $307.61M(-38.7%) |
| Dec 2019 | - | $502.00M(+94.0%) |
| Sep 2019 | $258.70M(+238.0%) | $258.70M(+8.7%) |
| Jun 2019 | - | $237.90M(+9.0%) |
| Mar 2019 | - | $218.20M(-10.5%) |
| Dec 2018 | - | $243.75M(+218.5%) |
| Sep 2018 | $76.53M(+16.7%) | $76.53M(+26.5%) |
| Jun 2018 | - | $60.48M(-33.9%) |
| Mar 2018 | - | $91.54M(+80.6%) |
| Dec 2017 | - | $50.70M(-22.7%) |
| Sep 2017 | $65.61M(-23.1%) | $65.61M(-12.7%) |
| Jun 2017 | - | $75.14M(-13.3%) |
| Mar 2017 | - | $86.63M(-15.2%) |
| Dec 2016 | - | $102.11M(+19.6%) |
| Sep 2016 | $85.37M(-13.6%) | $85.37M(+91.2%) |
| Jun 2016 | - | $44.65M(-27.4%) |
| Mar 2016 | - | $61.46M(-19.8%) |
| Dec 2015 | - | $76.60M(-22.4%) |
| Sep 2015 | $98.75M(-35.9%) | $98.75M(-10.7%) |
| Jun 2015 | - | $110.53M(-4.7%) |
| Mar 2015 | - | $116.01M(-9.0%) |
| Dec 2014 | - | $127.52M(-17.3%) |
| Sep 2014 | $154.16M(+447.8%) | $154.16M(-4.9%) |
| Jun 2014 | - | $162.18M(+1.0%) |
| Mar 2014 | - | $160.65M(+112.4%) |
| Dec 2013 | - | $75.63M(+168.7%) |
| Sep 2013 | $28.14M(+707.9%) | $28.14M(-14.9%) |
| Jun 2013 | - | $33.08M(+898.5%) |
| Mar 2013 | - | $3.31M(+10.9%) |
| Dec 2012 | - | $2.99M(-14.3%) |
| Sep 2012 | $3.48M | $3.48M(+45.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2012 | - | $2.39M(-34.9%) |
| Mar 2012 | - | $3.67M(-46.3%) |
| Dec 2011 | - | $6.84M(-15.9%) |
| Sep 2011 | $8.14M(+18.9%) | $8.14M(+48.2%) |
| Jun 2011 | - | $5.49M(-22.0%) |
| Mar 2011 | - | $7.04M(+28.8%) |
| Dec 2010 | - | $5.47M(-20.2%) |
| Sep 2010 | $6.85M(+238.9%) | $6.85M(-23.8%) |
| Jun 2010 | - | $8.98M(+246.4%) |
| Mar 2010 | - | $2.59M(-31.9%) |
| Dec 2009 | - | $3.81M(+88.6%) |
| Sep 2009 | $2.02M(-80.0%) | $2.02M(+5.8%) |
| Jun 2009 | - | $1.91M(-46.3%) |
| Mar 2009 | - | $3.56M(-53.4%) |
| Dec 2008 | - | $7.64M(-24.3%) |
| Sep 2008 | $10.09M(-58.2%) | $10.09M(-27.0%) |
| Jun 2008 | - | $13.82M(-29.2%) |
| Mar 2008 | - | $19.52M(-23.2%) |
| Dec 2007 | - | $25.42M(+5.4%) |
| Sep 2007 | $24.12M(-13.9%) | $24.12M(+605.0%) |
| Jun 2007 | - | $3.42M(-84.2%) |
| Mar 2007 | - | $21.59M(-23.6%) |
| Dec 2006 | - | $28.27M(+0.9%) |
| Sep 2006 | $28.02M(+24.3%) | $28.02M(-8.5%) |
| Jun 2006 | - | $30.63M(+84.7%) |
| Mar 2006 | - | $16.58M(-13.2%) |
| Dec 2005 | - | $19.11M(-15.3%) |
| Sep 2005 | $22.54M(+149.4%) | $22.54M(-10.5%) |
| Jun 2005 | - | $25.18M(+166.2%) |
| Mar 2005 | - | $9.46M(+34.1%) |
| Dec 2004 | - | $7.05M(-22.0%) |
| Sep 2004 | $9.04M(+567.1%) | $9.04M(-14.3%) |
| Jun 2004 | - | $10.55M(-5.3%) |
| Mar 2004 | - | $11.14M(+496.9%) |
| Dec 2003 | - | $1.87M(+37.7%) |
| Sep 2003 | $1.36M(+7225.9%) | $1.36M(>+9900.0%) |
| Jun 2003 | - | $5000.00(+25.0%) |
| Dec 2002 | - | $4000.00(-78.4%) |
| Sep 2002 | $18.50K(+6066.7%) | $18.50K(-67.4%) |
| Jun 2002 | - | $56.80K(+1858.6%) |
| Mar 2002 | - | $2900.00(+45.0%) |
| Dec 2001 | - | $2000.00(+566.7%) |
| Sep 2001 | $300.00(-85.0%) | $300.00(+50.0%) |
| Mar 2001 | - | $200.00(-33.3%) |
| Dec 2000 | - | $300.00(-85.0%) |
| Sep 2000 | $2000.00(+1900.0%) | $2000.00(+300.0%) |
| Jun 2000 | - | $500.00(-37.5%) |
| Mar 2000 | - | $800.00(+700.0%) |
| Dec 1999 | - | $100.00(0.0%) |
| Sep 1999 | $100.00(-90.0%) | $100.00(-91.7%) |
| Jun 1999 | - | $1200.00(-47.8%) |
| Mar 1999 | - | $2300.00 |
| Sep 1998 | $1000.00(-16.7%) | - |
| Sep 1997 | $1200.00 | - |
FAQ
- What is Arrowhead Pharmaceuticals, Inc. annual cash & cash equivalents?
- What is the all-time high annual cash & cash equivalents for Arrowhead Pharmaceuticals, Inc.?
- What is Arrowhead Pharmaceuticals, Inc. annual cash & cash equivalents year-on-year change?
- What is Arrowhead Pharmaceuticals, Inc. quarterly cash & cash equivalents?
- What is the all-time high quarterly cash & cash equivalents for Arrowhead Pharmaceuticals, Inc.?
- What is Arrowhead Pharmaceuticals, Inc. quarterly cash & cash equivalents year-on-year change?
What is Arrowhead Pharmaceuticals, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of ARWR is $919.37M
What is the all-time high annual cash & cash equivalents for Arrowhead Pharmaceuticals, Inc.?
Arrowhead Pharmaceuticals, Inc. all-time high annual cash & cash equivalents is $919.37M
What is Arrowhead Pharmaceuticals, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, ARWR annual cash & cash equivalents has changed by +$238.41M (+35.01%)
What is Arrowhead Pharmaceuticals, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of ARWR is $919.37M
What is the all-time high quarterly cash & cash equivalents for Arrowhead Pharmaceuticals, Inc.?
Arrowhead Pharmaceuticals, Inc. all-time high quarterly cash & cash equivalents is $1.10B
What is Arrowhead Pharmaceuticals, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, ARWR quarterly cash & cash equivalents has changed by +$238.41M (+35.01%)